ProCE Banner Activity

Phase III STOMP: Tecovirimat for the Treatment of Clade II Mpox

Conference Coverage
Slideset

Phase III STOMP study suggested that off-label tecovirimat was safe in individuals with clade II mpox but was not associated with improved resolution of skin lesions or pain control or statistically significant reductions in HMPXV detection.

Released: March 17, 2025

Expiration: September 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare